The next phase of innovation in ADCs

As antibody drug conjugates (ADCs) evolve beyond traditional boundaries, developers face mounting complexity, from high drug-to-antibody ratios (DARs) and multispecific formats to novel payloads and delivery challenges.

Discover how emerging technologies are helping overcome scientific, manufacturing, and regulatory hurdles, ensuring innovation translates into scalable, clinically viable therapies that meet the demands of modern oncology.